I

Immunome
D

IMNM

24.640
USD
1.40
(6.02%)
مغلق
حجم التداول
31,088
الربح لكل سهم
-2
العائد الربحي
-
P/E
-10
حجم السوق
2,787,602,023
المقالات
المزيد

العنوان: Immunome

القطاع: Healthcare
الصناعة: Biotechnology
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.